NASA has signed an agreement with StelSys LLC,
Baltimore, to fly experiments on the International Space
Station that will compare human liver-cell function in space
with that on Earth. This research could aid in StelSys’
development of treatment for people in need of liver

The research primarily will evaluate how human liver cells
process medicine in space and will add to further ground-
based research. Space Shuttle Discovery will deliver the
research equipment on mission STS- 111 scheduled for launch
in May 2002.

“This will be an excellent start for commercial use of space
technology,” said Dr. Neal Pellis, Chief, Biological Systems
Office, at NASA’s Johnson Space Center in Houston. “We hope
this is the first of many.”

The agreement to fly experiments in space comes just one year
after a groundbreaking licensing agreement between NASA and
StelSys intended to explore a new frontier in biotechnology.
The agreement focuses on the development of commercial
medical products and services using NASA’s Bioreactor
technology in four areas, including development of a liver-
assist device and a method for producing liver-cell
biomolecules and metabolites.

“Space is the gold-standard environment for this cutting-edge
cell research. Only in space, a true microgravity
environment, will we be able to isolate and study each of the
individual factors impacting cell function. This will allow
us to refine and then optimize ground-based Bioreactor
research,” said Dr. Fisk Johnson, president of Wisconsin-
based Fisk Ventures and co-founder of StelSys.

Utilizing the Bioreactor technology over the past year,
StelSys scientists have discovered a unique procedure to
accomplish long-term culturing of liver cells, which allows
the cells to maintain liver-specific functions for at least a
week, compared to only a day using traditional methods. In
addition, they have developed a prototype of a novel
“bioartificial” liver.

NASA invented the rotating Bioreactor as a way to study the
impact of microgravity on cellular growth on Earth and in
space. Traditional cell-growth research often produces
single-cell, pancake-like cultures which quickly lose normal
cell function. The Bioreactor works by gently spinning a
fluid medium filled with cells. The spinning motion
neutralizes most of gravity’s effects, creating a near-
weightless environment that allows cells to grow more freely,
in a three-dimensional manner.

“StelSys is committed to research with real-world benefit to
people. Our recent discoveries could lead to better, earlier
drug-candidate screening, which would speed up drug
development by pharmaceutical companies, and importantly, to
a longer life for the 25,000 people every year waiting for a
life-saving liver transplant,” said Dr. Paul Silber,
president of StelSys.

This research is being conducted under an agreement with
NASA’s Office of Biological and Physical Research,
Washington. The office is responsible for basic and applied
research using the low-gravity environment of space.

StelSys LLC is a biotechnology research company formed to
develop and commercialize real-world applications of the NASA
Bioreactor technology. The company maintains a core team of
researchers with expertise in cell biology and chemical

Additional information concerning this research is available
via the Internet at: